The gold-standard assay for measuring orexin deficiency in cerebrospinal fluid requires a lumbar puncture and radioactive materials. New findings could help advance testing alternatives for people with narcolepsy.
It will analyze once-daily and split-dose regimens of the oral orexin 2 receptor agonist in people with narcolepsy type 1 and type 2.
Brain imaging research identifies differences in brain structure and activity that could help in understanding and distinguishing IH.
Centessa Pharmaceuticals discontinues SerpinPC, an investigational hemophilia B therapy, to reallocate resources to its orexin receptor program.
Read More
TAK-861, an investigational oral orexin receptor 2 agonist, is being evaluated in a phase 3 study in patients with narcolepsy type 1.
Read More
Alkermes’ Q3 update reveals progress for ALKS 2680, an orexin 2 receptor agonist aimed at treating narcolepsy and idiopathic hypersomnia, with phase 2 trial completions expected in 2025.
Read More
Axsome Therapeutics is set to unveil data on AXS-12 and solriamfetol at Sleep Europe 2024, including results from a phase 3 trial in narcolepsy and solriamfetol’s impact on EDS.
Read More
Alkermes plc is presenting data from its phase 1b study of ALKS 2680, a novel oral orexin 2 receptor agonist, at Sleep Europe 2024.
Read More
Takeda will present additional data from phase 2b and long-term extension trials of its investigational orexin receptor 2 agonist, TAK-861.
Read More
Centessa plans to advance the orexin receptor 2 agonist into phase 2 studies for narcolepsy and idiopathic hypersomnia in late 2024.
Read More
Preclinical data on ORX142, showing its effectiveness in promoting wakefulness at low doses in non-human primates, will be presented at Sleep Europe 2024.
Read More
Centessa Pharmaceuticals progresses its orexin receptor 2 agonist program, initiating a phase 1 trial for ORX750 and advancing ORX142 as a development candidate for a range of sleep-wake and neurological disorders.
Read More
Jazz reports second-quarter earnings, with growth driven in part by a 13% increase in Xywav sales.
Read More
Alkermes recapsQ2 highlights in developing ALKS 2680 for narcolepsy, including positive study results and the initiation of a phase 2 trial.
Read More
Alkermes discusses the development, clinical trials, and safety of its orexin 2 receptor agonist drug candidate for narcolepsy and idiopathic hypersomnia.
Read More
Eisai Inc is set to begin enrolling patients for a clinical trial to test the effectiveness and safety of E2086 for narcolepsy type 1.
Read More
The phase 1b study of ALKS 2680, presented at SLEEP 2024, demonstrates improvements in wakefulness and alertness in patients with narcolepsy type 1.
Read More
The investigational orexin receptor 2 agonist showed statistically significant and clinically meaningful improvements across primary and secondary endpoints in patients with narcolepsy type 1.
Read More